SMS Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
SMS Pharmaceuticals's earnings have been declining at an average annual rate of -4.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.6% per year. SMS Pharmaceuticals's return on equity is 10.5%, and it has net margins of 7.7%.
Key information
-4.9%
Earnings growth rate
-5.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.6% |
| Return on equity | 10.5% |
| Net Margin | 7.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Revenue & Expenses Breakdown
How SMS Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 7,685 | 593 | 716 | 0 |
| 30 Jun 24 | 7,384 | 570 | 666 | 0 |
| 31 Mar 24 | 7,093 | 498 | 658 | 0 |
| 31 Dec 23 | 6,129 | 361 | 615 | 0 |
| 30 Sep 23 | 6,002 | 288 | 598 | 0 |
| 30 Jun 23 | 5,930 | 150 | 571 | 0 |
| 31 Mar 23 | 5,221 | -71 | 548 | 0 |
| 31 Dec 22 | 4,335 | -42 | 535 | 0 |
| 30 Sep 22 | 4,060 | 9 | 532 | 0 |
| 30 Jun 22 | 4,211 | 259 | 517 | 0 |
| 31 Mar 22 | 5,199 | 622 | 515 | 0 |
| 31 Dec 21 | 6,348 | 789 | 499 | 0 |
| 30 Sep 21 | 6,612 | 911 | 475 | 0 |
| 30 Jun 21 | 6,172 | 791 | 442 | 0 |
| 31 Mar 21 | 5,632 | 625 | 415 | 0 |
| 31 Dec 20 | 4,911 | 458 | 405 | 0 |
| 30 Sep 20 | 4,226 | 319 | 398 | 0 |
| 30 Jun 20 | 4,130 | 308 | 386 | 0 |
| 31 Mar 20 | 4,143 | 316 | 410 | 0 |
| 31 Dec 19 | 4,206 | 386 | 398 | 0 |
| 30 Sep 19 | 4,412 | 405 | 389 | 0 |
| 30 Jun 19 | 4,606 | 406 | 366 | 0 |
| 31 Mar 19 | 4,667 | 400 | 372 | 0 |
| 31 Mar 18 | 4,639 | 317 | 343 | 0 |
| 31 Mar 17 | 4,388 | 285 | 288 | 0 |
| 31 Mar 16 | 6,032 | 409 | 406 | 0 |
| 31 Dec 15 | 5,902 | 391 | 579 | 0 |
| 30 Sep 15 | 5,828 | 396 | 566 | 0 |
| 30 Jun 15 | 5,651 | 343 | 330 | 0 |
| 31 Mar 15 | 5,793 | 352 | 533 | 0 |
| 31 Dec 14 | 5,730 | 358 | 504 | 0 |
| 30 Sep 14 | 5,624 | 327 | 493 | 0 |
| 30 Jun 14 | 5,567 | 326 | 282 | 0 |
| 31 Mar 14 | 5,180 | 204 | 455 | 0 |
| 31 Dec 13 | 3,976 | 686 | 372 | 0 |
Quality Earnings: SMSPHARMA has high quality earnings.
Growing Profit Margin: SMSPHARMA's current net profit margins (7.7%) are higher than last year (4.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SMSPHARMA's earnings have declined by 4.9% per year over the past 5 years.
Accelerating Growth: SMSPHARMA's earnings growth over the past year (106.2%) exceeds its 5-year average (-4.9% per year).
Earnings vs Industry: SMSPHARMA earnings growth over the past year (106.2%) exceeded the Pharmaceuticals industry 20.4%.
Return on Equity
High ROE: SMSPHARMA's Return on Equity (10.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 23:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SMS Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |